Resources for each step of the treatment journey with AUSTEDO
Downloadable resources for prescribers
Use this questionnaire to help identify and assess the impact of TD when evaluating patients.
Fill out this form to enroll your patient in Teva’s Shared Solutions®.
Use this template to write an appeals letter, which payers may need to appeal a denial of coverage for AUSTEDO.
Use this template to write a letter to establish medical necessity, which payers may require for treatment with AUSTEDO.
Downloadable resources for your patients with TD
A useful resource for patients as they begin their treatment journey. Patients and their carepartners can use this tracking tool to record when they take AUSTEDO, as well as any changes in their TD.
This brochure provides answers to important questions your patients with TD and their carepartners may have when starting treatment with AUSTEDO.
This brochure provides an overview of patient support services offered through Shared Solutions, including help with access, affordability, and adherence.
Videos to help you support your patients with TD
Mechanism of Action
VMAT2 inhibition can help regulate dopamine function.1
TD Movements Over Time
See the treatment journey of Charlene, a patient taking AUSTEDO, and find information on titration and the effects on symptom control.
Faces of TD: Patient case studies
Brian, a patient with bipolar disorder, who has had his routine disrupted by TD.
Lisa, a patient with schizophrenia, whose movements are starting to impact her time with her family.
Patricia, a patient with major depressive disorder, who is also taking an antihypertensive.
TD Talks: Informative videos on TD evaluation and treatment
Dr. Rajeev Kumar talks about AUSTEDO for the treatment of TD.
Dr. Rakesh Jain discusses drug metabolism as a crucial consideration for TD treatment.
Amber Hoberg, PMHNP-BC, discusses the importance of assessing and managing TD.
Demystifying EPS: TD Is Distinct—a 3-part series on the importance of differential diagnosis
Chapter 1: Considering the landscape of antipsychotic usage.
Chapter 2: Opposing mechanisms of TD and drug-induced parkinsonism (DIP).
Chapter 3: Differential diagnosis of TD.
TD virtual assessments, demonstrated by Dr. Arvinder Walia
A long virtual assessment, with full view of the patient’s body.
A short virtual assessment, without full view of the patient’s body.
EPS, extrapyramidal symptoms; VMAT2, vesicular monoamine transporter 2.
REFERENCE: 1. Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215-1238.